Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.

Haiying QinLila YangJohn A ChukinasNirali N ShahSamiksha TarunMarie PouzollesChristopher D ChienLisa M NiswanderAnthony R WelchNaomi TaylorSarah K TasianTerry J Fry

Published in: Journal for immunotherapy of cancer (2022)

clinicaltrials.gov; NCT03971799.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
cell therapy
nk cells
stem cells
acute lymphoblastic leukemia